Press release
Immuno-Oncology Drugs Market Overview Till 2025 | Industry Insights, Trends, Analysis, And Forecast
According to World Health Organization (WHO), cancer is one of the major non-communicable diseases and the second-leading cause of death worldwide. According to International Agency for Research on Cancer (IARC) in 2012, there were around 14.1 million new cases, 8.8 million deaths, and 32.6 million people living with cancer worldwide. Immuno-oncology therapy is effective for treatment of cancers such as melanoma, bladder cancer, head and neck cancer, leukemia, lung, multiple myeloma, lymphoma, and renal cancer. Furthermore, immuno-oncology has less side effect than chemotherapy, radiation therapy, and surgery. There are many immuno-oncology drugs in the pipeline such as CAR-T cell therapy offered by Juno Therapeutics, Inc and Kite Pharma. Immuno-oncology drugs has proven clinical profile and increasing approvals to include more indicationfor existing drugs such as nivolumab is in turn expected to boost growth of the immuno-oncology drugs market.To understand Research Methodology @ https://www.coherentmarketinsights.com/insight/request-sample/1271
However, high costs associated with therapy is restraining growth of the immuno-oncology drugs market. Immuno oncology drugs prescribed with chemotherapy increases the cancer treatment cost. According to Immuno-Oncology Summit Europe 2017, combination of immunotherapy with chemotherapy and targeted therapy improves survival rate of cancer patient. In 2017, Merck & Company received approval for immune checkpoint inhibitor brand Keytruda (pembrolizumab) for its use in combination with other anti-cancer drugs such as pemetrexed and carboplatin in non-squamous non-small cell lung cancer.
U.S. to dominate the immuno-oncology drugs market, owing to high prevalence of cancer
The U.S. has a robust healthcare infrastructure and is characterized by high availability of novel anti-cancer therapy options. According to a report published in American Cancer Society’s Cancer Journal for Clinicians, around 1,735,350 new cancer cases are estimated to be diagnosed in 2018 in U.S., including around 87,290 cases of melanoma, for which drugs such as ipilimumab (Brand-Yeroy) and pembrolimumab (Brand-Keytruda) have been approved. Furthermore, expansion of indications for already approved drug would open up new opportunities for immuno-oncology market. Currently, atezolizumab (Brand-Tecentriq) is indicated for type of cancers such as melanoma, bladder cancer, head and neck cancer FDA granted accelerated approval to Tecentriq for the treatment of people with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy
Durvalumab (Imfinzi) was approved in 2017 as immune checkpoint inhibitor, which blocks interaction of PD-L1 with PD-1 and CD80.
In December 2017, nivolumab (Opdivo) received approval for adjuvant treatment of melanoma.
In August 2017, Novartis received approval for CAR-T therapy named Kymriah for children and young adult with B- cell lymphoblastic lymphoma.
Gilead Life Science completed the acquisition of Kite pharma Ltd. in October 2017, for around US$ 1.3 billion. Gilead’s CAR-T therapy Yescarta received FDA approval in October 2017 to treat non-Hodgkin lymphoma.
Celgene Corporation, in January 2018, announced acquisition of Juno Therapeutics, Inc. for US$ 9 billion. Through this acquisition, Celgene Corporation would gain access to novel CAR-T therapy, which is in pipeline of Juno Therapeutics.
Amgen received FDA approval in 2017, for Imlygic, which is an oncolytic virus to treat melanoma.
In March 2017, FDA approved the avelumab (Bavencio) in metastatic Merkel cell carcinoma which is rare disease, EMD serono and Pfizer Inc. jointly developed it.
Key players operating in the immuno-oncology drugs market include Amgen Inc.,
AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co, F. Hoffmann-La Roche AG, Johnson & Johnson,, Novartis International AG, Abbvie, Inc., Pfizer Inc., EMD Serono, Inc. and Gilead Lifescinces Inc.
Complete Report Details @ https://www.coherentmarketinsights.com/ongoing-insight/immuno-oncology-drugs-market-1271
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentnews.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Immuno-Oncology Drugs Market Overview Till 2025 | Industry Insights, Trends, Analysis, And Forecast here
News-ID: 960978 • Views: …
More Releases from CMI - Market Research

Dental Braces Market - Industry Insights, Size, Share, Growth, Analysis, Trends …
Dental braces are commonly used in orthodontic treatment to improve an individual’s orofacial appearance. Malocclusions (tooth overcrowding or crooked teeth), overbites, deep bites, cross bites, under bites, and incorrect jaw positions are some of the conditions that affect the orofacial appearance and other orthodontic problems. Malocclusions often lead to lack of confidence in a person. Increasing number of cases of malocclusions, jaw disease, jaw pain, tooth decay, and tooth loss…

Colon and Rectal Cancer Drugs Market – Industry Size, Growth, outlook and Anal …
Colon and rectal cancer are often grouped together, as they have many common features. Rate of colorectal cancer is increasing among the millennials in the U.S. The American Cancer Society (ACS) estimates that there will be around 97,220 new cases of colon cancer and around 43,030 new cases of rectal cancer registered in the U.S. in 2018. Moreover, owing to increasing risk of colorectal cancer, in May 2018, ACS updated…

Clostridium Difficile Infection Treatment Market Growth, Size, Trends and Analys …
Clostridium difficile, which produces gram-positive bacterium, is an anaerobic toxin that gets transmitted through fecal-oral route. Clostridium difficile infection occurs during antibiotic treatment or can be caused due to healthcare associated infection with clinical manifestation ranging from asymptomatic infection to watery diarrhea or serious intestinal condition such as colitis and colonic perforation. This infection can be diagnosed by enzyme immunoassays for toxins or Clostridium difficile glutamate dehydrogenase (GDH) and nucleic…

Cervical Cancer Drugs Market - Size, Share, Growth | Trend and Analysis, 2018-20 …
Cervical cancer develops in women’s cervix, and mainly affects sexually active women aged between 30 and 45. Cervical cancer often shows no symptoms in early stages. However, the death rate of cervical cancer can be significantly reduced with use of Pap test (Papanicolaou test): a screening procedure which can detect the changes in the cervix before the cancer develops. There are different types of cervical cancer, out of which two…
More Releases for Immuno
Organic Dispersion To Drive The Immuno-Oncology Market
The immuno-oncology therapy has shown excellent results in various clinical trials and in patients being treated with immune-oncology therapy. Immuno-oncology therapies can leverage patients' immune system and re-program the same to attack cancer cells, providing a safe and effective alternative. There has been an increasing demand for immuno-oncology therapy as several traditional methods used in the treatment of cancer such as chemotherapy, radiation therapy, and surgery, etc. carry the risk…
Immuno Oncology Assays Market Size, Immuno Oncology Assays Market Prediction, Im …
The Immuno Oncology Assays Market Report examines the Immuno Oncology Assays industry from a variety of angles, including market size, status, trends, and forecasts. It also gives a quick rundown of the top competitors and development opportunities in the market. The research contains a comprehensive study of the keyword market, split by companies, regions, types, and applications.
The research goes into great detail on several aspects that have been studied as…
Next Gen Immuno-Oncology Congress - 4th Annual MarketsandMarkets
In the past decade, many scientific breakthroughs have been achieved through research including success in recent years of cancer immunotherapy with monoclonal antibodies, cancer vaccines, adoptive cell therapy and immune-checkpoint therapy. Personalized immunotherapy with various combinations will be the next promising strategy for the future cancer treatment direction.
Register as a Delegate at https://www.reportsnreports.com/events/4th-annual-marketsandmarkets-next-gen-immuno-oncology-congress/register
o 30+ experts from academia and industry will be presenting their current work in Immuno-Oncology, Latest updates on…
Cell Therapy to Transform Immuno Oncology Landscape
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights:
• Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026
• Cell Therapy Clinical Trial Insight by Indication, Company & Country
• Global Cell Therapy Clinical Pipeline: 767 Cell Therapies
• Globally Marketed Cell Therapies: 25 Cell Therapies
• Maximum Number of Marketed Cell Therapies In USA: 15 Therapies
• Price & Product Insight By Region/Country
• Regional Analysis of the Cell Therapy Market
Download…
Less than 4 Weeks until Immuno-Therapy Experts Gather at the Immuno-Oncology Con …
There’s just under 4 weeks until SMi’s Immuno-Oncology Conference commences in London on the 26th and 27th September (www.immuno-oncology-conference.com/openpr).
The event aims to propagate thought-provoking discussions about the future of Immuno-Oncology between industry leaders, and update delegates on current key areas for development, advancements in therapy and revisions of regulations.
The study of immuno-oncology has been ever-present in recent news, with biomarkers in melanoma having been recently identified by Dana-Farber Cancer Institute…
Immuno-Oncology Conference, London – agenda released
Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies.
SMi's Immuno-Oncology Conference (26 – 27 September 2018, London, UK) will focus on a few key areas of the field with representation of the whole industry, under each area. These areas will be drawn together to look towards the future of Immuno-oncology and how the field can progress.
Agenda - Valuable time is spent to…